(Q33818706)

29 July 2017

1 reference

title

Interferon beta in multiple sclerosis: is IL-12 suppression the key? (English)

1 reference

29 July 2017

0 references

Karp CL

1

1 reference

PubMed ID

10637555

29 July 2017

Biron CA

series ordinal

2

1 reference

PubMed ID

10637555

29 July 2017

Irani DN

series ordinal

3

1 reference

29 July 2017

1 January 2000

1 reference

29 July 2017

1 reference

29 July 2017

21

1 reference

29 July 2017

24-28

1 reference

29 July 2017

1

1 reference

Experimental immunotherapies for multiple sclerosis.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Management of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Beta-interferon and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Mechanisms of action of interferon-beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

IL-12 unmasks latent autoimmune disease in resistant mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Interleukin-13: central mediator of allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Increased release of interleukin-12p40 in MS: association with intracerebral inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Selective expression of an interleukin-12 receptor component by human T helper 1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Human recombinant interferon-beta influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

Two roads diverged: interferon alpha/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901541-8

7 January 2021

10.1016/S0167-5699(99)01541-8

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10637555